Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

firstwordpharmaMay 26, 2021

Tag: Focal Segmental Glomerulosclerosis , proteinuria , EGFR

PharmaSources Customer Service